Trials In Focus: FDA Guidance Aims To Tackle Challenges In Multi-Endpoint Trials
Guidance Targets ‘Multiplicity Problem’
Beam Therapeutics also announced that it dosed the first patient in its Phase I/II sickle cell disease trial; Vyne stepped into the increasingly competitive vitiligo space, while Tracon moved further into sarcomas in its checkpoint inhibitor program, and Telix started a small trial of its drug in brain cancer.
You may also be interested in...
Incyte Signals Increasing Focus In Dermatology With Villaris Buyout
With Opzelura approved for vitiligo in July, Incyte acquires Villaris and its preclinical IL-15-targeted antibody to potentially add to its vitiligo portfolio.
Clinuvel Plots Competition To Incyte In Vitiligo Space
The Australian company is steadily growing its photoprotective drug in adults with erythropoietic protoporphyria but also sees a big opportunity in the pigment loss disorder.
Beam Therapeutics’ Base-Edited CAR-T Placed On Hold
Beam is the latest allogeneic CAR-T developer to face a regulatory hold-up, but other candidates using its pioneering base-editing technology are now progressing.